Industry
Optimapharm
Total Trials
6
Recruiting
0
Active
2
Completed
1
Success Rate
50.0%-37% vs avg
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 65/100
Failure Rate
16.7%
1 terminated/withdrawn out of 6 trials
Success Rate
50.0%
-36.5% vs industry average
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
100%
1 of 1 completed trials have results
Key Signals
1 with results
Enrollment Performance
Analytics
Phase 2
3(60.0%)
N/A
1(20.0%)
Phase 1
1(20.0%)
5Total
Phase 2(3)
N/A(1)
Phase 1(1)
Activity Timeline
Global Presence
Loading network data...
Clinical Trials (6)
Showing 6 of 6 trials
NCT03322865Phase 2Active Not Recruiting
Obinutuzumab in Marginal Zone Lymphoma
Role: collaborator
NCT03474744Phase 2Active Not Recruiting
Copanlisib and Rituximab in Marginal Zone Lymphoma Patients
Role: collaborator
NCT05646303Phase 2Unknown
Psilocybin-Assisted Psychotherapy in Adults With Alcohol Use Disorder (AUD)
Role: collaborator
NCT02948088Completed
Tenosynovial Giant Cell Tumors (TGCT) Observational Platform Project
Role: collaborator
NCT04160130Not ApplicableUnknown
RHEIA (Randomized researcH in womEn All Comers With Aortic Stenosis)
Role: lead
NCT04195373Phase 1Withdrawn
A Safety Study of TMV-018 in Patients With Tumors of the Gastrointestinal Tract
Role: collaborator
All 6 trials loaded